Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Investigating the Mechanism Through Which Follistatin Affects Vessel Contractility in Essential Hypertension

FY 2022-23

Summary
Hypertension (HTN) is the leading cause of mortality and cardiovascular disease worldwide. Essential or primary HTN (90-95% of cases) is defined as elevated blood pressure with no known medical cause. Secondary HTN is less common (5-10%) and is caused by medical conditions such as renal disease. HTN pathogenesis is associated with alterations in resistance vessels such as elevated vascular tone, media thickening and reduced relaxation. The Krepinsky lab has previously shown that follistatin (FST), a glycoprotein inhibitor of members of the Transforming Growth Factor ? (TGF?) family such as activins, reduced blood pressure in the Spontaneously Hypertensive Rat (SHR) model of essential HTN. Wire myography experiments also showed that acute FST exposure significantly reduced ex-vivo vessel contractility and calcium release induced by potassium (KCl) in both SHR vessels and in vessels of normotensive, Wistar Kyoto Rats (WKY). This study aims to elucidate the mechanism through which FST inhibits potassium-induced contraction in WKY and SHR vessels using first-order branches of resistance mesenteric arteries for wire myography studies. As activin A has been shown to inhibit ATP-sensitive K+ channels and increase voltage-gated Ca2+ channel activity, I will test whether FST effects may be caused by activin A neutralization. Inhibitors and activators of ATP-sensitive K+ channels will also be used to test whether FST enables increased K-ATP activity. Using the Fluo-4-AM calcium assay on vessels and cultured smooth muscle cells of WKY and SHR, I will also test calcium influx modulation by FST and activin A inhibition. My studies will explore how FST, a potential novel therapeutic antihypertensive, affects vessel contractility in HTN, generating critical data for clinical use.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486253
Name
Sadat Afjeh Seyedeh Niki
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Mechanism Through Which Follistatin Affects Vessel Contractility in Essential Hypertension
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Follistatin; Hypertension; Potassium Channel Blockers; Smooth Muscle Cells; Spontaneously Hypertensive Rats; Vasculature; Vessel Contraction; Wistar Kyoto Rats
Abstract
Hypertension (HTN) is the leading cause of mortality and cardiovascular disease worldwide. Essential or primary HTN (90-95% of cases) is defined as elevated blood pressure with no known medical cause. Secondary HTN is less common (5-10%) and is caused by medical conditions such as renal disease. HTN pathogenesis is associated with alterations in resistance vessels such as elevated vascular tone, media thickening and reduced relaxation. The Krepinsky lab has previously shown that follistatin (FST), a glycoprotein inhibitor of members of the Transforming Growth Factor ? (TGF?) family such as activins, reduced blood pressure in the Spontaneously Hypertensive Rat (SHR) model of essential HTN. Wire myography experiments also showed that acute FST exposure significantly reduced ex-vivo vessel contractility and calcium release induced by potassium (KCl) in both SHR vessels and in vessels of normotensive, Wistar Kyoto Rats (WKY). This study aims to elucidate the mechanism through which FST inhibits potassium-induced contraction in WKY and SHR vessels using first-order branches of resistance mesenteric arteries for wire myography studies. As activin A has been shown to inhibit ATP-sensitive K+ channels and increase voltage-gated Ca2+ channel activity, I will test whether FST effects may be caused by activin A neutralization. Inhibitors and activators of ATP-sensitive K+ channels will also be used to test whether FST enables increased K-ATP activity. Using the Fluo-4-AM calcium assay on vessels and cultured smooth muscle cells of WKY and SHR, I will also test calcium influx modulation by FST and activin A inhibition. My studies will explore how FST, a potential novel therapeutic antihypertensive, affects vessel contractility in HTN, generating critical data for clinical use.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sadat Afjeh, Seyedeh Niki
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~